MRNA could possibly reach as high as 250’s before or after the earnings report on 10 Mar.
Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth.
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
…
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company
MRNA
to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.
…
The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth.
First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
…
The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company
MRNA
to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development. …
The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
Comment:
I have no idea what is happening here and why it is selling off so deep, but given the expected profits it will get in 2021 I am positive it will go to ATH within months.
So just holding and watching.
So just holding and watching.
Comment:
bought more today
Now, finally and hopefully, we are going to ATH.